Refined ADA testing strategy to overcome sRANKL interference in denosumab/FKS518 immunogenicity assessment
These findings underscore the importance of early interference assessment and mitigation. A multi-tiered strategy, encompassing screening, confirmatory, and specificity tiers, provided a robust solution applicable to programs facing similar challenges.
Authors
- Corinne Petit-Frere
- Martin Ullmann (ORCID: https://orcid.org/0000-0002-3088-3209)
- Anna Lucia Buccarello
- Adriano L. Soares de Souza
Institutions
- Fresenius Kabi (Czechia) (CZ)
Publication Details
- Journal
- Bioanalysis
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1080/17576180.2025.2607080
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00